SHATTUCK

Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease. Compounds derived from Shattuck's ARC platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead program, SL-172154 (SIRPα-Fc-CD40L), is designed to block the CD47 immune checkpoint and simultaneously activate the CD40 receptor, a member of the tumor necrosis factor superfamily, is being evaluated in multiple Phase 1 clinical trials... We are creating a new class of fusion proteins through our Agonist Redirected Checkpoint (ARC®) technology. Solving a fundamental structural limitation of other modalities, ARC molecules target and unlock the TNFr superfamily in a unique fashion while simultaneously blocking an immune checkpoint... At Shattuck Labs, we promise to treat your data with respect and will not share..

Also known as: Shattuck Labs, Shattuck Labs, Inc

Primary location: Durham United States